1. Home
  2. ZNTL vs FPH Comparison

ZNTL vs FPH Comparison

Compare ZNTL & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • FPH
  • Stock Information
  • Founded
  • ZNTL 2014
  • FPH 2009
  • Country
  • ZNTL United States
  • FPH United States
  • Employees
  • ZNTL N/A
  • FPH N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • FPH Real Estate
  • Sector
  • ZNTL Health Care
  • FPH Finance
  • Exchange
  • ZNTL Nasdaq
  • FPH Nasdaq
  • Market Cap
  • ZNTL 227.0M
  • FPH 271.3M
  • IPO Year
  • ZNTL 2020
  • FPH 2017
  • Fundamental
  • Price
  • ZNTL $2.25
  • FPH $4.03
  • Analyst Decision
  • ZNTL Buy
  • FPH
  • Analyst Count
  • ZNTL 8
  • FPH 0
  • Target Price
  • ZNTL $10.50
  • FPH N/A
  • AVG Volume (30 Days)
  • ZNTL 1.6M
  • FPH 249.8K
  • Earning Date
  • ZNTL 02-25-2025
  • FPH 01-23-2025
  • Dividend Yield
  • ZNTL N/A
  • FPH N/A
  • EPS Growth
  • ZNTL N/A
  • FPH 35.57
  • EPS
  • ZNTL N/A
  • FPH 0.70
  • Revenue
  • ZNTL $40,560,000.00
  • FPH $196,899,000.00
  • Revenue This Year
  • ZNTL N/A
  • FPH N/A
  • Revenue Next Year
  • ZNTL N/A
  • FPH N/A
  • P/E Ratio
  • ZNTL N/A
  • FPH $5.81
  • Revenue Growth
  • ZNTL N/A
  • FPH 79.04
  • 52 Week Low
  • ZNTL $2.16
  • FPH $2.83
  • 52 Week High
  • ZNTL $18.07
  • FPH $4.39
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 32.94
  • FPH 63.53
  • Support Level
  • ZNTL $2.16
  • FPH $3.60
  • Resistance Level
  • ZNTL $2.93
  • FPH $4.15
  • Average True Range (ATR)
  • ZNTL 0.28
  • FPH 0.13
  • MACD
  • ZNTL -0.07
  • FPH 0.05
  • Stochastic Oscillator
  • ZNTL 7.69
  • FPH 80.59

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Commercial. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: